X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES BIOCON LTD JUBILANT LIFE SCIENCES/
BIOCON LTD
 
P/E (TTM) x 15.4 50.6 30.5% View Chart
P/BV x 4.6 7.4 61.7% View Chart
Dividend Yield % 0.4 0.2 254.5%  

Financials

 JUBILANT LIFE SCIENCES   BIOCON LTD
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
BIOCON LTD
Mar-18
JUBILANT LIFE SCIENCES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1871,188 15.7%   
Low Rs65305 21.3%   
Sales per share (Unadj.) Rs364.368.7 530.2%  
Earnings per share (Unadj.) Rs6.87.6 90.7%  
Cash flow per share (Unadj.) Rs24.514.0 175.4%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %2.40.1 1,778.1%  
Book value per share (Unadj.) Rs164.986.3 191.0%  
Shares outstanding (eoy) m159.28600.00 26.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.310.9 3.2%   
Avg P/E ratio x18.498.9 18.6%  
P/CF ratio (eoy) x5.153.4 9.6%  
Price / Book Value ratio x0.88.6 8.8%  
Dividend payout %43.813.2 330.9%   
Avg Mkt Cap Rs m20,061447,900 4.5%   
No. of employees `0006.26.1 100.6%   
Total wages/salary Rs m11,0529,311 118.7%   
Avg. sales/employee Rs Th9,383.06,705.8 139.9%   
Avg. wages/employee Rs Th1,786.91,514.2 118.0%   
Avg. net profit/employee Rs Th176.3736.9 23.9%   
INCOME DATA
Net Sales Rs m58,03441,234 140.7%  
Other income Rs m1912,062 9.2%   
Total revenues Rs m58,22443,296 134.5%   
Gross profit Rs m5,7868,291 69.8%  
Depreciation Rs m2,8123,851 73.0%   
Interest Rs m3,237615 526.4%   
Profit before tax Rs m-725,887 -1.2%   
Minority Interest Rs m-286213 -134.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,569 44.4%   
Profit after tax Rs m1,0904,531 24.1%  
Gross profit margin %10.020.1 49.6%  
Effective tax rate %-965.926.7 -3,624.1%   
Net profit margin %1.911.0 17.1%  
BALANCE SHEET DATA
Current assets Rs m29,28041,486 70.6%   
Current liabilities Rs m38,91221,413 181.7%   
Net working cap to sales %-16.648.7 -34.1%  
Current ratio x0.81.9 38.8%  
Inventory Days Days8464 131.9%  
Debtors Days Days5194 53.8%  
Net fixed assets Rs m55,71250,661 110.0%   
Share capital Rs m1553,000 5.2%   
"Free" reserves Rs m20,96848,808 43.0%   
Net worth Rs m26,26551,808 50.7%   
Long term debt Rs m17,16917,898 95.9%   
Total assets Rs m88,60699,897 88.7%  
Interest coverage x1.010.6 9.2%   
Debt to equity ratio x0.70.3 189.2%  
Sales to assets ratio x0.70.4 158.7%   
Return on assets %4.95.2 94.8%  
Return on equity %4.28.7 47.5%  
Return on capital %11.69.6 120.1%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00412,058 182.5%   
Fx outflow Rs m11,7497,348 159.9%   
Net fx Rs m10,2554,710 217.7%   
CASH FLOW
From Operations Rs m8,0266,621 121.2%  
From Investments Rs m-1,744-6,840 25.5%  
From Financial Activity Rs m-4,447-2,397 185.5%  
Net Cashflow Rs m1,834-2,612 -70.2%  

Share Holding

Indian Promoters % 45.6 40.4 112.9%  
Foreign collaborators % 3.5 20.6 17.0%  
Indian inst/Mut Fund % 8.7 8.4 103.6%  
FIIs % 21.2 10.7 198.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 19.9 106.0%  
Shareholders   23,815 109,995 21.7%  
Pledged promoter(s) holding % 15.9 0.0 39,625.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Dec 12, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS